TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07587021: Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

Sponsor: YolTech Therapeutics Co., Ltd · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 36 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$896,400

Rescue Site Savings

+$597,600

Unlock Full NCT07587021 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07587021 Rescue Dossier →